Key facts
- March Biosciences’s last known valuation is $47.0M (Jan 2025).
- It has raised $33.2M across 1 recorded rounds; the latest was Early Stage VC ($22.1M) in Oct 2024.
- Notable investors include Keiretsu Forum, Texas Medical Center, Alexandria Venture Investments, Mission BioCapital, Modi Ventures — 15 tracked in total.
- March Biosciences has filed 2 Form Ds with the SEC since 2023, most recently Oct 2024 ($22.1M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for March Biosciences
Funding rounds
1 roundsAbout March Biosciences
Developer of cell-based therapies designed for the treatment of hematological cancers. The company integrates biologically informed target selection with simplified, gene-editing-free CAR-T engineering and a streamlined manufacturing process that emphasizes cell functionality and consistency, enabling oncology researchers to access novel therapeutic approaches for malignancies that lack effective targeted treatments.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2021
- Employees
- 7
- Website
- march.bio/
- Ownership
- Privately Held (backing)
March Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in March Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on March Biosciences in its N-PORT filings yet. We sweep new filings monthly.